Pay in 4 interest-free payments of $10.50 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
3-3 mg/kg once day in mouse models
which binds to the HM/PIF binding pocket rather than the ATP-binding site
57(Pt 1):76-8
on the production of inflammatory mediators by rheumatoid synovial fibroblasts
SBI-0206965 was usually used at 10 µM final concentration in vitro
PAI-039 - CAS# 393105-53-8 size:2mg solid 3-3 mg/kg once day inPAI 039, CAS No. 393105 53 8, is a novel plasminogen activator inhibitor 1 (PAI 1) inhibitor. The pharmacokinetic profile of PAI 039 indicated an oral bioavailability of 43 + 15. 3% and a plasma half life of 6. 2 + 1. 3 h. PAI 039 is an orally active prothrombolytic drug that inhibits PAI 1 and accelerates fibrinolysis while maintaining normal coagulation in a model of coronary occlusion . PAI 039 exerts antithrombotic efficacy in rat models of
US$ 1490.50
US$ 1024.00